Jazz Pharmaceuticals (JAZZ) Curent Deferred Tax Liability (2012 - 2015)

Jazz Pharmaceuticals has reported Curent Deferred Tax Liability for 4 years, with the latest figure at $9.4 million in Q3 2015.

• For the quarter ending Q3 2015, Curent Deferred Tax Liability rose 50.46% year-over-year to $9.4 million; the trailing twelve-month figure through Sep 2015 stood at $9.4 million (up 50.46% YoY), and the FY2014 full-year result was $9.4 million, up 50.66% from the prior year.
• Curent Deferred Tax Liability for Q3 2015 stood at $9.4 million, roughly flat from $9.4 million in the prior quarter.
• The five-year high for Curent Deferred Tax Liability was $9.4 million in Q2 2015, with the low at $259000.0 in Q1 2013.
• Average Curent Deferred Tax Liability over 4 years is $5.3 million, with a median of $6.3 million recorded in 2013.
• Year-over-year, Curent Deferred Tax Liability soared 2316.6% in 2014 and soared 50.46% in 2015.
• Tracing JAZZ's Curent Deferred Tax Liability over 4 years: stood at $275000.0 in 2012, then jumped by 2176.0% to $6.3 million in 2013, then jumped by 50.66% to $9.4 million in 2014, then fell by 0.14% to $9.4 million in 2015.
• The last three Curent Deferred Tax Liability figures came in at $9.4 million (Q3 2015), $9.4 million (Q2 2015), and $9.4 million (Q1 2015), per Business Quant data.

Peer Comparison